Meeting
2018 ASCO Annual Meeting
A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.
Authors
Xu Shan Sun
CHRU Jean Minjoz, Besancon Cedex, France
Xu Shan Sun , Christian Sire , Yungan Tao , Laurent Martin , Marc Alfonsi , Jean Briac Prevost , Michel Rives , Cedrik Lafond , Jean-Marc Tourani Sr., Julian Biau , Lionnel Geoffrois , Alexandre Coutte , Xavier Liem , Elodie Vauleon , Franck Drouet , Jean-François Ramee , Gabriel Waksi , Laura Sinigaglia , Anne Auperin , Jean Bourhis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02707588
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6018)
DOI
10.1200/JCO.2018.36.15_suppl.6018
Abstract #
6018
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
First Author: Thiago Bueno Oliveira Sr.
Poster
2021 ASCO Annual Meeting
Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
First Author: Christophe Le Tourneau
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil
Poster
2013 ASCO Annual Meeting
Phase II trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell carcinoma of the head and neck (LA SCCHN): Feasibility and 2-year OS.
First Author: Thomas Kuhnt